Discovery of a cancer promoter offers pathway to overcome drug resistance

September 12, 2018, St. Jude Children's Research Hospital
A chance experiment in the Grosveld laboratory hinted that a third mTOR complex might exist that was assembled by a protein called ETV7. Credit: St. Jude Children's Research Hospital

Geneticists at St. Jude Children's Research Hospital have discovered a previously unknown cell growth mechanism that makes a wide range of cancers resistant to rapamycin and related drugs. The finding offers the promise of new drug therapies that can overcome that resistance to treat cancers including leukemia and tumors in the brain and other organs.

The researchers, led by Gerard Grosveld, Ph.D., member and chair of the Department of Genetics, published their findings as an advance online publication of the journal Science Advances.

The enzyme mTOR is a central regulator of and is often abnormally activated in many cancers to drive their proliferation. The drug rapamycin and its close relatives, called rapalogs, are known to plug into the mTOR molecule to block its action. However, the drugs have proven only marginally effective against cancers, because most are resistant to the drugs.

Researchers had known that the mTOR enzyme was controlled in its many functions by being embedded in two protein complexes, called mTORC1 and mTORC2. However, a chance experiment in the Grosveld laboratory hinted that a third mTOR complex might exist that was assembled by a protein called ETV7. The experiment associated ETV7 over-activation with over-activation of mTOR.

By exploring genomic data on cancers, the researchers found that ETV7 was abnormally activated in a large fraction of many cancers, including , , pediatric solid tumors and the brain medulloblastoma. In fact, one publication reported ETV7 to be among the top 10 percent of over-represented proteins in liver .

The researchers' experiments with cell cultures revealed that ETV7 spurred cells to grow faster by hyper activating mTOR. But mysteriously, ETV7 was not part of mTORC1 or mTORC2.

Further experiments revealed that ETV7 directed assembly of a distinctly different complex, which they dubbed mTORC3. The researchers established that mTORC3 was distinct by showing that it lacked components specific to the other two complexes. Also, the investigators found the other complexes lacked ETV7. Importantly, researchers showed that mTORC3 showed complete rapamycin resistance.

Researchers showed that eliminating ETV7 in rapamycin resistant tumor cells rendered them sensitive to rapamycin. In studies with a mouse model developing muscle tumors, investigators found that the production of mTORC3 accelerated tumor formation and made the tumors more aggressive.

The researchers called the discovery of mTORC3 a "paradigm shift" in the study of mTOR that "identifies a novel target for anticancer development."

Said Grosveld, "This new complex has not been on anybody's radar screen, even though mTOR complexes have been studied for the last 25 years. We have developed solid data for the existence of mTORC3, and now, we are seeking to isolate and identify the components of the complex."

Future studies will also pursue drugs that specifically inhibit mTORC3 by interfering with ETV7. When combined with drugs to block mTORC1 and mTORC2, such therapies could make a wide range of cancers sensitive to rapalogs.

Explore further: Architecture of cellular control center mTORC2 elucidated

More information: "ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer" Science Advances (2018). DOI: 10.1126/sciadv.aar3938 ,

Related Stories

Architecture of cellular control center mTORC2 elucidated

February 20, 2018
The protein complex mTORC2 controls cellular lipid and carbohydrate metabolism. Researchers from the Biozentrum of the University of Basel and the ETH Zurich have now succeeded in deciphering the 3-D structure of this important ...

Common genetic pathway could be conduit to pediatric tumor treatment

November 7, 2013
Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

Aberrant mTOR signaling impairs whole body physiology

August 11, 2014
The protein mTOR is a central controller of growth and metabolism. Deregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer. In the current issue of the journal ...

Study finds biomarker targets to make drugs more effective in fighting cancer

December 27, 2017
A new study published in Nature Communications and led by University of Kentucky Markey Cancer Center researcher Qing-Bai She identifies biomarker targets that may make existing drugs more effective in fighting certain cancers.

Why can't mTOR inhibitors kill cancer? Study explains

October 5, 2017
Anti-cancer drugs called mTOR inhibitors slow the growth of cancer cells but show limited ability to cause cancer cell death. New studies explain why.

New generation mTOR inhibitors aim to combat drug-resistant tumors

May 18, 2016
Howard Hughes Medical Institute scientists have designed a potential cancer therapy that uses a unique strategy to block mTOR, a molecule that helps drive the growth of many tumors. In animal experiments, the drug reduces ...

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.